Homepage
Author:
GEN Ilac ve Saglik Urunleri A.S.
Posted Date:
June 8, 2026
GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson’s Disease
GEN Ilac ve Saglik Urunleri A.S.
June 8, 2026
GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson’s Disease
GEN Ilac ve Saglik Urunleri A.S.
March 16, 2026
